UNSPSC 51132233: Aspirin/caffeine/gelsemium/hyoscyamus

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132233 Aspirin/caffeine/gelsemium/hyoscyamus is a Commodity code, but the recent state and local procurement activity tagged under it shows little alignment with the code's nominal scope. The three most recent opportunities — Seminole County's naloxone and drug deactivation systems procurement, Texas HHS Commission's direct-to-manufacturer pharmacy initiative RFI, and Minnesota MMCAP's generic multi-source pharmaceuticals and OTC products RFP — involve prescription medications, naloxone (an opioid antagonist), and broad pharmaceutical supply categories rather than the specific fixed-combination analgesic-caffeine product the code names. The issuing bodies span county health departments, state HHS agencies, and multistate cooperative purchasing alliances; Seminole County is seeking quarterly deliveries of 1,900 units of naloxone annually through an IFB posted June 30, 2026, while MMCAP is recruiting manufacturers to supply generic pharmaceuticals and OTC products to multiple state and local government facilities across participating jurisdictions including Oregon, Minnesota, and others through an RFP due March 26, 2026.

The geographic footprint includes Florida (Seminole County), Texas (HHS Commission), and Minnesota (MMCAP administration), with MMCAP's cooperative structure serving a broader multistate membership base. The Seminole County IFB (IFB60459723LAS, response due July 26, 2023) is the most narrowly scoped of the recent opportunities, addressing a specific health-emergency supply need with fixed quarterly delivery schedules and two-year initial terms plus one-year renewal options. The Texas RFI (HHS0017013, April 3, 2026) is exploratory market intelligence rather than a competitive solicitation, designed to inform future formal procurement of direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The MMCAP RFP (S1070000015802, due March 26, 2026) is the largest in nominal scope, requiring manufacturers to supply hundreds of pharmaceuticals and OTC products with specific NDC coding, cGMP and DSCSA certifications, and relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with contract awards effective July 1, 2026. The code's mismatch with the recent opportunities suggests limited relevance for vendors specializing in the fixed-combination analgesic products the UNSPSC category nominally describes.